Is Early Onset Androgenic Alopecia a Marker of Metabolic Syndrome and Carotid Artery Atherosclerosis in Young Indian Male Patients?

Harmeet Singh Banger, Suresh Kumar Malhotra, Sohan Singh, Mridula Mahajan, Harmeet Singh Banger, Suresh Kumar Malhotra, Sohan Singh, Mridula Mahajan

Abstract

Background: Androgenic alopecia (AGA) is a common cosmetically and psychosocially distressing condition. High androgen level contributes to the development of atherosclerosis, thrombosis leading to hypertension and hypercholesterolemia.

Objectives: To study the clinico-epidemiological profile of AGA and the presence of metabolic syndrome (MetS) and carotid artery atherosclerosis in male patients with early onset AGA as compared to controls.

Materials and methods: In this case-control study, 100 male patients of age 18-35 years with AGA and an equal number of age-matched healthy controls attending skin and STD OPD were included. Assessment of the degree of hair loss, evaluation of MetS and carotid artery color Doppler for the atherosclerotic plaque was done in all patients.

Results: Statistically significant number of patients with early onset AGA 22/100 (22%) (P < 0.05) fulfilled the criteria for MetS compared to 8/100 (8%) in the control group. There were statistically significant differences in mean values of waist circumference, serum triglycerides, serum cholesterol, systolic blood pressure, diastolic blood pressure, fasting glucose concentration, and very low-density lipoprotein (LDL). However, no significant differences were observed in the mean values of high-density lipoprotein cholesterol and LDL cholesterol. The atherosclerotic plaque was found in two patients of the study group, and no plaque was found in control patients.

Conclusion: We suggest that all men with AGA should be thoroughly investigated, and lifestyle changes should be started in the early period of life so as to reduce the risk of various problems associated with MetS. AGA can be considered as an early marker for MetS.

Keywords: Androgenic alopecia; carotid artery atherosclerosis; metabolic syndrome.

Figures

Figure 1
Figure 1
Family history in study group and control group
Figure 2
Figure 2
Abnormal biomedical parameters in study and control group

References

    1. Trüeb RM. Molecular mechanisms of androgenetic alopecia. Exp Gerontol. 2002;37:981–90.
    1. Sinclair RD, Dawber RP. Androgenetic alopecia in men and women. Clin Dermatol. 2001;19:167–78.
    1. Sasmaz S, Senol M, Ozcan A, Dogan G, Tuncer C, Akyol O, et al. The risk of coronary heart disease in men with androgenetic alopecia. J Eur Acad Dermatol Venereol. 1999;12:123–5.
    1. Mansouri P, Mortazavi M, Eslami M, Mazinani M. Androgenetic alopecia and coronary artery disease in women. Dermatol Online J. 2005;11:2.
    1. Matilainen V, Koskela P, Keinänen-Kiukaanniemi S. Early androgenetic alopecia as a marker of insulin resistance. Lancet. 2000;356:1165–6.
    1. Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol. 2007;17:220–2.
    1. Sadighha A, Zahed GM. Evaluation of lipid levels in androgenetic alopecia in comparison with control group. J Eur Acad Dermatol Venereol. 2009;23:80–1.
    1. Mosley JG, Gibbs AC. Premature grey hair and hair loss among smokers: A new opportunity for health education? BMJ. 1996;313:1616.
    1. Hawk E, Breslow RA, Graubard BI. Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. Cancer Epidemiol Biomarkers Prev. 2000;9:523–7.
    1. Oh BR, Kim SJ, Moon JD, Kim HN, Kwon DD, Won YH, et al. Association of benign prostatic hyperplasia with male pattern baldness. Urology. 1998;51:744–8.
    1. Su LH, Chen TH. Association of androgenetic alopecia with smoking and its prevalence among Asian men: A community-based survey. Arch Dermatol. 2007;143:1401–6.
    1. Nabaie L, Kavand S, Robati RM, Sarrafi-Rad N, Kavand S, Shahgholi L, et al. Androgenic alopecia and insulin resistance: Are they really related? Clin Exp Dermatol. 2009;34:694–7.
    1. Shahar E, Heiss G, Rosamond WD, Szklo M. Baldness and myocardial infarction in men: The atherosclerosis risk in communities study. Am J Epidemiol. 2008;167:676–83.
    1. Abdel Fattah NS, Darwish YW. Androgenetic alopecia and insulin resistance: Are they truly associated? Int J Dermatol. 2011;50:417–22.
    1. Matilainen V, Laakso M, Hirsso P, Koskela P, Rajala U, Keinänen-Kiukaanniemi S. Hair loss, insulin resistance, and heredity in middle-aged women. A population-based study. J Cardiovasc Risk. 2003;10:227–31.
    1. Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, et al. Androgenetic alopecia in men aged 40-69 years: Prevalence and risk factors. Br J Dermatol. 2003;149:1207–13.
    1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet. 2006;367:1747–57.
    1. Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: A 26-year follow-up of the Framingham population. Am Heart J. 1986;111:383–90.
    1. Su LH, Chen TH. Association of androgenetic alopecia with metabolic syndrome in men: A community-based survey. Br J Dermatol. 2010;163:371–7.
    1. Schnohr P, Lange P, Nyboe J, Appleyard M, Jensen G. Gray hair, baldness, and wrinkles in relation to myocardial infarction: The Copenhagen City Heart Study. Am Heart J. 1995;130:1003–10.
    1. Ford ES, Freedman DS, Byers T. Baldness and ischemic heart disease in a national sample of men. Am J Epidemiol. 1996;143:651–7.
    1. Lotufo PA, Chae CU, Ajani UA, Hennekens CH, Manson JE. Male pattern baldness and coronary heart disease: The Physicians' Health Study. Arch Intern Med. 2000;160:165–71.
    1. Lesko SM, Rosenberg L, Shapiro S. A case-control study of baldness in relation to myocardial infarction in men. JAMA. 1993;269:998–1003.
    1. Miric D, Fabijanic D, Giunio L, Eterovic D, Culic V, Bozic I, et al. Dermatological indicators of coronary risk: A case-control study. Int J Cardiol. 1998;67:251–5.
    1. Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R. Androgenetic alopecia and cardiovascular risk factors in men and women: A comparative study. J Am Acad Dermatol. 2010;63:420–9.
    1. Rebora A. Baldness and coronary artery disease: The dermatologic point of view of a controversial issue. Arch Dermatol. 2001;137:943–7.
    1. Hamilton JB. Patterned loss of hair in man; types and incidence. Ann N Y Acad Sci. 1951;53:708–28.
    1. Norwood OT. Male pattern baldness: Classification and incidence. South Med J. 1975;68:1359–65.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA. 2001;16(285):2486–97.
    1. WHO⁄IASO⁄IOTF. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia; 2000.
    1. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic syndrome: Results from the prospective cardiovascular munster (PROCAM) study. Int J Obes (Lond) 2008;32(Suppl 2):S11–6.
    1. Hirsso P, Rajala U, Hiltunen L, Jokelainen J, Keinänen-Kiukaanniemi S, Näyhä S. Obesity and low-grade inflammation among young Finnish men with early-onset alopecia. Dermatology. 2007;214:125–9.
    1. Mumcuoglu C, Ekmekci TR, Ucak S. The investigation of insulin resistance and metabolic syndrome in male patients with early-onset androgenetic alopecia. Eur J Dermatol. 2011;21:79–82.
    1. Acibucu F, Kayatas M, Candan F. The association of insulin resistance and metabolic syndrome in early androgenetic alopecia. Singapore Med J. 2010;51:931–6.
    1. Spinler SA. Challenges associated with metabolic syndrome. Pharmacotherapy. 2006;26(12 Pt 2):209S–17S.
    1. Buchholz AC, Bugaresti JM. A review of body mass index and waist circumference as markers of obesity and coronary heart disease risk in persons with chronic spinal cord injury. Spinal Cord. 2005;43:513–8.
    1. Canoy D. Distribution of body fat and risk of coronary heart disease in men and women. Curr Opin Cardiol. 2008;23:591–8.
    1. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, et al. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: A population-based prospective study. Circulation. 2007;116:2933–43.
    1. 1st International Congress on “Prediabetes and the Metabolic Syndrome”; Berlin, Germany. 2005.
    1. Matilainen VA, Mäkinen PK, Keinänen-Kiukaanniemi SM. Early onset of androgenetic alopecia associated with early severe coronary heart disease: A population-based, case-control study. J Cardiovasc Risk. 2001;8:147–51.
    1. Guzzo CA, Margolis DJ, Johnson J. Lipid profiles, alopecia, and coronary disease: Any relationship? Dermatol Surg. 1996;22:481.
    1. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am J Cardiol. 2003;91:11C–7C.
    1. Sharrett AR, Sorlie PD, Chambless LE, Folsom AR, Hutchinson RG, Heiss G, et al. Relative importance of various risk factors for asymptomatic carotid atherosclerosis versus coronary heart disease incidence: The Atherosclerosis Risk in Communities Study. Am J Epidemiol. 1999;149:843–52.
    1. Hirsso P, Laakso M, Matilainen V, Hiltunen L, Rajala U, Jokelainen J, et al. Association of insulin resistance linked diseases and hair loss in elderly men. Finnish population-based study. Cent Eur J Public Health. 2006;14:78–81.
    1. Sainte Marie Y, Toulon A, Paus R, Maubec E, Cherfa A, Grossin M, et al. Targeted skin overexpression of the mineralocorticoid receptor in mice causes epidermal atrophy, premature skin barrier formation, eye abnormalities, and alopecia. Am J Pathol. 2007;171:846–60.
    1. Choi KM, Kim SM, Kim YE, Choi DS, Baik SH, Lee J. International Diabetes Federation. Prevalence and cardiovascular disease risk of the metabolic syndrome using National Cholesterol Education Program and International Diabetes Federation definitions in the Korean population. Metabolism. 2007;56:552–8.
    1. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–8.
    1. Salaroli LB, Barbosa GC, Mill JG, Molina MC. Prevalence of metabolic syndrome in population-based study, Vitória, ES-Brazil. Arq Bras Endocrinol Metabol. 2007;51:1143–52.
    1. Martínez Candela J, Franch Nadal J, Romero Ortiz J, Cánovas Domínguez C, Gallardo Martín A, López Yepes ML. Predictive capacity of the diagnostic criteria of metabolic syndrome on the insulin-resistance and the coronary risk. Med Clin (Barc) 2007;129:601–6.
    1. Calbo Mayo JM, Terrancle de Juan I, Fernández Jiménez P, Rodríguez Martín MJ, Martínez Díaz V, Santisteban López Y, et al. Prevalence of metabolic syndrome in the province of Albacete (Spain) Rev Clin Esp. 2007;207:64–8.
    1. Cipriani R, Ruzza G, Foresta C, Veller Fornasa C, Peserico A. Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia. Br J Dermatol. 1983;109:249–52.
    1. Cotton SG, Nixon JM, Carpenter RG, Evans DW. Factors discriminating men with coronary heart disease from healthy controls. Br Heart J. 1972;34:458–64.
    1. Dogramaci AC, Balci DD, Balci A, Karazincir S, Savas N, Topaloglu C, et al. Is androgenetic alopecia a risk for atherosclerosis? J Eur Acad Dermatol Venereol. 2009;23:673–7.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever